| ²é¿´: 170 | »Ø¸´: 2 | |||
| µ±Ç°Ö÷ÌâÒѾ´æµµ¡£ | |||
liuhui3230гæ (³õÈëÎÄ̳)
|
[½»Á÷]
ÇóÖúcnkiΪʲô²é²»Á˦Á¦Â¦ÃµÈÏ£À°×Öĸ¡£
|
||
| ÇóÖúcnkiΪʲô²é²»Á˦Á¦Â¦ÃµÈÏ£À°×Öĸ¡£Ð»Ð»°ïÖú£¡ |
» ²ÂÄãϲ»¶
284Çóµ÷¼Á
ÒѾÓÐ10È˻ظ´
һ־Ըɽ¶«´óѧҩѧѧ˶Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
07»¯Ñ§280·ÖÇóµ÷¼Á
ÒѾÓÐ4È˻ظ´
298-Ò»Ö¾Ô¸Öйúũҵ´óѧ-Çóµ÷¼Á
ÒѾÓÐ12È˻ظ´
Çó²ÄÁÏ£¬»·¾³×¨Òµµ÷¼Á
ÒѾÓÐ3È˻ظ´
335Çóµ÷¼Á
ÒѾÓÐ5È˻ظ´
Çóµ÷¼Á
ÒѾÓÐ7È˻ظ´
Ò»Ö¾Ô¸¼ª´ó»¯Ñ§322Çóµ÷¼Á
ÒѾÓÐ4È˻ظ´
»·¾³Ñ§Ë¶288Çóµ÷¼Á
ÒѾÓÐ8È˻ظ´
341Çóµ÷¼Á(Ò»Ö¾Ô¸ºþÄÏ´óѧ070300)
ÒѾÓÐ6È˻ظ´
liuhui3230
гæ (³õÈëÎÄ̳)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- Ìû×Ó: 2
- ÔÚÏß: 5·ÖÖÓ
- ³æºÅ: 849542
- ×¢²á: 2009-09-16
- רҵ: ÆÕÍâ¿Æ
2Â¥2009-10-20 18:36:28
mdzhao
ľ³æ (ÕýʽдÊÖ)
- Ó¦Öú: 0 (Ó×¶ùÔ°)
- ½ð±Ò: 2850.7
- Ìû×Ó: 875
- ÔÚÏß: 11.6Сʱ
- ³æºÅ: 858600
- ×¢²á: 2009-09-28
- ÐÔ±ð: MM
- רҵ: ÐÅÏ¢×ÊÔ´¹ÜÀí
¡ï
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
Сľ³æ(½ð±Ò+0.5):¸ø¸öºì°ü£¬Ð»Ð»»ØÌû½»Á÷
|
Ôõô²»Äܲ鰡£¬¿ÉÒÔ²éµÄ¡£¼ûÏÂÃæÓæÁ ¦Â ¦ÃÔÚCNKIÌâÃû×ֶεļìË÷½á¹û 1 ¡¶¹æ·¶Ê¹ÓæÂÉöÉÏÏÙËØÄÜÊÜÌå×èÖͼÁ¡·ÇÄÈ»³ö¯ ½¡¿µ´óÊÓÒ° 2008/10 2 Growth Inhibiton of Human Breast Cancer Cell Line MDA-MB-231 by Rosiglitazone through Activation of PPAR¦Ã Tao Zhang~1 Qian Zhang~1 Daixiong Chen~1 Jianxin Jiang~2 Qixin Zhou~31 Key Laboratory of Cell Engineering of Guizhou Province Chinese Journal of Clinical Oncology 2008/06 3 HIF-1¦ÁÔÚ¹¬¾±°©Ï¸°û²»Í¬È±Ñõʱ¼äµÄ±í´ïÇé¿ö¼°ÆäÓëѪ¹ÜÉú³ÉºÍϸ°ûµòÍöµÄ¹ØÏµ Íõ·ïõ ¸£ÖÝ×ÜҽԺѧ±¨ 2008/04 4 ºËÒò×Ó¦ÊBÖ×Áö»µËÀÒò×Ó-¦ÁºÍϸ°û¼ä𤸽·Ö×Ó-1ÔÚÌØ·¢ÐԻưßǰĤÖеıí´ï¼°ÁÙ´²ÒâÒå ¼ÖÖ¾½Ü ÖйúÒ©ÎïÓëÁÙ´² 2008/S1 5 ÌÇÄò²¡×㲿À£Ññ»¼Õß°×½éËØ-1¦Â¶Ô³ÉÏËάϸ°ûÔöÖ³¼°»ùÖʽðÊôµ°°×ø-2ºÍ»ùÖʽðÊôµ°°×ø-9µÄÓ°Ïì ФÕý»ª ÖйúÂýÐÔ²¡Ô¤·ÀÓë¿ØÖÆ 2008/06 6 ѪÇåÊÝËØÖ×Áö»µËÀÒò×Ó-¦ÁÓë·ÊÅÖ³õ·¢ÐÍ2ÐÍÌÇÄò²¡Ïà¹ØÐÔÑо¿ ÍõÓ¢¹û ÖйúÒ©ÎïÓëÁÙ´² 2008/S2 7 ù·ÓËá¶Ô¸ßÌÇÓÕµ¼µÄ´óÊóϵĤϸ°ûÔöÉúºÍ¸ßÌÇÓÕµ¼µÄTGF-¦Â¡¢CTGF±í´ïµÄÓ°Ïì ³Â¿¡Ó¢ ÖйúÌÇÄò²¡ÔÓÖ¾ 2008/01 8 ·ÊÅÖÕßÍøÄ¤Ö¬·¾×éÖ¯ÖÐÖ¬ÁªËØ¡¢Ö×Áö»µËÀÒò×Ó¦Á mRNA±í´ï¼°ÆäÓëÒȵºËصֿ¹Ïà¹ØÐÔµÄÑо¿ ³ÂÃ÷ÎÀ ÖйúÌÇÄò²¡ÔÓÖ¾ 2008/01 9 ·ÊÅÖÄÐÐÔ»¼ÕßѪ½¬8ÒìǰÁÐÏÙËØF_(2¦Á)Óëϸ°û𤸽·Ö×ӵĹØÏµ Àî¾ê Öлª¸ßѪѹÔÓÖ¾ 2008/10 10 ÎüÑÌÓ°Ïì¦Á_1ÊÜÌå×èÖͼÁºÍCa~(2+)ͨµÀÞ׿¹¼ÁµÄ½µÑ¹ÁÆÐ§ ·½½¨ Öлª¸ßѪѹÔÓÖ¾ 2008/12 |
3Â¥2009-10-20 22:10:49













»Ø¸´´ËÂ¥